ROR1 Inhibitors

Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is a type I membrane protein belonging to the receptor tyrosine kinase (RTK) family, although it functions atypically compared to classical RTKs. ROR1 is crucial in early development, with expression patterns tightly regulated and predominantly silenced in adult tissues. However, aberrant expression of ROR1 has been observed in various malignancies, including chronic lymphocytic leukemia, breast cancer, and lung adenocarcinoma, where it contributes to tumor growth, survival, and metastasis. ROR1's role in cancer is linked to its ability to modulate critical signaling pathways involved in cell survival, proliferation, and migration, such as the Wnt/β-catenin pathway, JAK/STAT pathway, and PI3K/AKT pathway.

The inhibition of ROR1 activity in cancer therapy focuses on disrupting the signaling pathways that promote tumor cell survival and proliferation. Strategies for ROR1 inhibition include the use of monoclonal antibodies designed to bind specifically to ROR1, curbing its interaction with ligands or signaling partners and thereby blocking downstream signaling events that contribute to tumor progression. Another approach involves the use of small molecule inhibitors that target the kinase domain of ROR1, inhibiting its enzymatic activity and subsequent signaling. Additionally, chimeric antigen receptor (CAR) T-cell therapy has been explored, where T cells are engineered to recognize and attack ROR1-expressing tumor cells, providing a highly specific method of targeting cancers that overexpress ROR1.